13/05/2026 – AB Science reports its revenues for the year 2025 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:AB Science announces the successful completion of a EUR 3.2 million private placementNextNext post:AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per shareRelated PostsAB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026AB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 204217 June 2026
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS9 June 2026
Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors27 April 2026
